23 Mar, 2018
- Market News
- Analyst Reports
- Personal Finance
Spark Therapeutics Inc (NASDAQ: ONCE) Luxturna, the first gene therapy in the U.S., has been approved by the Food and Drug Administration. The gene therapy is intended to treat a rare, inherited retinal disease that could possibly cause blindness. U..
Revance Therapeutics Inc (NASDAQ: RVNC) is a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions. On Tuesday shares of the Revance jumped about 10% a after the company announced its n..
Sage Therapeutics (NASDAQ: SAGE) shares are down about 15% after the a clinical-stage biopharmaceutical company announced the results from the Phase 3 STATUS Trial of did not meet the primary endpoint. The trial of brexanolone (SAGE-547) in the trea..
Novartis AG (NYSE: NVS) announced Wednesday that the US Food and Drug Administration (FDA) has approved Kymriah (TM)(tisagenlecleucel) suspension for intravenous infusion, the first chimeric antigen receptor T cell (CAR-T) therapy, for the treatment..
Novartis AG (NYSE: NVS) is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The U.S. Food and Drug Administration will ask a panel of advisers to focus on the safety of ..
Endo International Plc. (NASDAQ: ENDP) announced on Thursday that it will voluntarily remove its powerful opioid painkiller, Opana ER, a month after the U.S. Food and Drug Administration's withdrawal request amid the growing opioid abuse crisis ..
Clovis Oncology Inc. (NASDAQ: CLVS) is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. The company’s shares jumped ab..
All rights reserved.